Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 14, 1984 - Issue 4
26
Views
8
CrossRef citations to date
0
Altmetric
Original Article

The effect of bromazepam (Lexotan) administration on antipyrine pharmacokinetics in humans

, , , &
Pages 321-326 | Received 12 Oct 1983, Published online: 30 Sep 2009
 

Abstract

1. Six healthy volunteers were given a standard regimen of bromazepam (Lexotan®) (6 mg t.d.s.) for five days. Compliance with the study protocol was demonstrated by measuring drug concentrations at steady state.

2. Steady-state levels of 3-hydroxybromazepam were also determined. These were found to be much lower than the concentrations of bromazepam. Since the metabolite is known to be less active than the parent drug, it is likely that the metabolite will contribute little to the pharmacological effects of the drug in humans.

3. Antipyrine pharmacokinetics were studied immediately before bromazepam administration was started, after the dosing schedule had been completed and one week after dosing had been discontinued. There were no significant changes in the disposition of antipyrine on any occasion. Therefore, although previous studies have demonstrated enzyme induction in laboratory animals given high doses of bromazepam, similar effects are unlikely to occur in humans being treated with therapeautic doses of the compound.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.